Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Albert Martin who wrote (7905)	6/12/1999 9:27:00 AM
From: James Baker	Read Replies (1) \| Respond to of 9523

Can we trust either the author or the analyst who makes this kind of error? <<<Chaffkin also emphasizes the fact that Pfizer spends nearly $2.8 billion a year in R & D, that's more than double that of competitors such as Merck (NYSE: MRK - Quotes, News, Boards) which spends about $700 million per year. >>>> According to MERCK's 1998 annual report they spend $1.8 billion up from $1.6 billion in 1997 on their R&D. They are correct that PFE is currently spending more on R&D than others BUT NOT by a factor of 4! I own both MRK and PFE and would like the facts stated accurately. Jim